Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for visceral obesity in adults with HIV without diabetes
2026-526738-18-00Phase 2Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of semaglutide in Abdominal adiposity (ABCD) (2 arms), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Percentage change in visceral adipose tissue area. Planned start Oct 2026; status: authorised.
02
Drugs
03
Conditions
Abdominal adiposity (ABCD)
Beyond the preview
Go deeper on 2026-526738-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526738-18-00.